EML4-ALK in non-small-cell lung cancer: The breathtaking progress from benchtop to Phase III clinical trial

Geoffrey Y. Ku; Gilberto De Lima Lopes

doi:10.2217/thy.10.83

EML4-ALK in non-small-cell lung cancer: The breathtaking progress from benchtop to Phase III clinical trial

Geoffrey Y. Ku, Gilberto De Lima Lopes

School of Medicine

Research output: Contribution to journal › Review article › peer-review

2 Scopus citations

Abstract

EML4-ALK is a fusion oncogene found in approximately 5% of patients with non-small-cell lung cancer. It was first discovered in 2007, and is found predominantly in those who never smoke or light smokers (≤10 pack/year tobacco history), younger patients and those with adenocarcinoma histology. It occurs almost exclusively in patients without mutations in K-ras or EGFR. Completed Phase I and II trials suggest significant clinical activity of an ALK kinase inhibitor, PF-02341066 (crizotinib), in patients with advanced non-small-cell lung cancer who harbor an ALK translocation. A Phase III evaluation of crizotinib versus chemotherapy in the second-line setting is ongoing.

Original language	English (US)
Pages (from-to)	55-61
Number of pages	7
Journal	Therapy
Volume	8
Issue number	1
DOIs	https://doi.org/10.2217/thy.10.83
State	Published - Jan 2011

Keywords

EML4-ALK
lung cancer
oncogene
targeted therapy

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.2217/thy.10.83

Cite this

@article{2814dbabad2343b79b3ef83bd16cdc27,

title = "EML4-ALK in non-small-cell lung cancer: The breathtaking progress from benchtop to Phase III clinical trial",

abstract = "EML4-ALK is a fusion oncogene found in approximately 5% of patients with non-small-cell lung cancer. It was first discovered in 2007, and is found predominantly in those who never smoke or light smokers (≤10 pack/year tobacco history), younger patients and those with adenocarcinoma histology. It occurs almost exclusively in patients without mutations in K-ras or EGFR. Completed Phase I and II trials suggest significant clinical activity of an ALK kinase inhibitor, PF-02341066 (crizotinib), in patients with advanced non-small-cell lung cancer who harbor an ALK translocation. A Phase III evaluation of crizotinib versus chemotherapy in the second-line setting is ongoing.",

keywords = "EML4-ALK, lung cancer, oncogene, targeted therapy",

author = "Ku, {Geoffrey Y.} and {De Lima Lopes}, Gilberto",

year = "2011",

month = jan,

doi = "10.2217/thy.10.83",

language = "English (US)",

volume = "8",

pages = "55--61",

journal = "Therapy",

issn = "1475-0708",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - EML4-ALK in non-small-cell lung cancer

T2 - The breathtaking progress from benchtop to Phase III clinical trial

AU - Ku, Geoffrey Y.

AU - De Lima Lopes, Gilberto

PY - 2011/1

Y1 - 2011/1

N2 - EML4-ALK is a fusion oncogene found in approximately 5% of patients with non-small-cell lung cancer. It was first discovered in 2007, and is found predominantly in those who never smoke or light smokers (≤10 pack/year tobacco history), younger patients and those with adenocarcinoma histology. It occurs almost exclusively in patients without mutations in K-ras or EGFR. Completed Phase I and II trials suggest significant clinical activity of an ALK kinase inhibitor, PF-02341066 (crizotinib), in patients with advanced non-small-cell lung cancer who harbor an ALK translocation. A Phase III evaluation of crizotinib versus chemotherapy in the second-line setting is ongoing.

AB - EML4-ALK is a fusion oncogene found in approximately 5% of patients with non-small-cell lung cancer. It was first discovered in 2007, and is found predominantly in those who never smoke or light smokers (≤10 pack/year tobacco history), younger patients and those with adenocarcinoma histology. It occurs almost exclusively in patients without mutations in K-ras or EGFR. Completed Phase I and II trials suggest significant clinical activity of an ALK kinase inhibitor, PF-02341066 (crizotinib), in patients with advanced non-small-cell lung cancer who harbor an ALK translocation. A Phase III evaluation of crizotinib versus chemotherapy in the second-line setting is ongoing.

KW - EML4-ALK

KW - lung cancer

KW - oncogene

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=78650926770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650926770&partnerID=8YFLogxK

U2 - 10.2217/thy.10.83

DO - 10.2217/thy.10.83

M3 - Review article

AN - SCOPUS:78650926770

SN - 1475-0708

VL - 8

SP - 55

EP - 61

JO - Therapy

JF - Therapy

IS - 1

ER -

EML4-ALK in non-small-cell lung cancer: The breathtaking progress from benchtop to Phase III clinical trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this